Promis Neurosciences Stock Today
| PMN Stock | USD 1.03 0.07 7.29% |
Performance0 of 100
| Odds Of DistressOver 81
|
ProMIS Neurosciences is selling at 1.03 as of the 23rd of November 2024; that is 7.29% up since the beginning of the trading day. The stock's open price was 0.96. ProMIS Neurosciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for ProMIS Neurosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of October 2024 and ending today, the 23rd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of July 2007 | Category Healthcare | Classification Health Care |
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimers disease , amyotrophic lateral sclerosis , and multiple system atrophy in Canada. ProMIS Neurosciences, Inc. The company has 32.69 M outstanding shares of which 239.78 K shares are at this time shorted by investors with about 2.64 days to cover. More on ProMIS Neurosciences
Moving together with ProMIS Stock
| 0.71 | ME | 23Andme Holding | PairCorr |
| 0.75 | VALN | Valneva SE ADR | PairCorr |
| 0.61 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against ProMIS Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
ProMIS Stock Highlights
| CoChairman CoFounder | Neil MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Promis Neurosciences Inc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ProMIS Neurosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ProMIS Neurosciences' financial leverage. It provides some insight into what part of ProMIS Neurosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ProMIS Neurosciences (PMN) is traded on NASDAQ Exchange in USA. It is located in 1920 Yonge Street, Toronto, ON, Canada, M4S 3E2 and employs 6 people. ProMIS Neurosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 33.65 M. ProMIS Neurosciences runs under Biotechnology sector within Health Care industry. The entity has 32.69 M outstanding shares of which 239.78 K shares are at this time shorted by investors with about 2.64 days to cover.
ProMIS Neurosciences has about 8.95 M in cash with (14.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.24, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check ProMIS Neurosciences Probability Of Bankruptcy
Ownership AllocationProMIS Neurosciences owns a total of 32.69 Million outstanding shares. Over half of ProMIS Neurosciences' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check ProMIS Ownership Details
ProMIS Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Royal Bank Of Canada | 2024-06-30 | 713 | |
| Td Waterhouse Canada Inc | 2024-06-30 | 133 | |
| Wells Fargo & Co | 2024-06-30 | 20.0 | |
| Northwestern Mutual Wealth Management Co | 2024-06-30 | 4.0 | |
| Jpmorgan Chase & Co | 2024-06-30 | 3.0 | |
| Ubs Group Ag | 2024-06-30 | 0.0 | |
| Northeast Financial Consultants, Inc | 2024-06-30 | 0.0 | |
| Sphera Funds Management Ltd. | 2024-06-30 | 1.8 M | |
| Ally Bridge Group (ny) Llc | 2024-06-30 | 1.1 M | |
| Affinity Asset Advisors, Llc | 2024-09-30 | 30.6 K | |
| Bank Of Montreal | 2024-06-30 | 30.4 K |
ProMIS Neurosciences Historical Income Statement
ProMIS Stock Against Markets
ProMIS Neurosciences Corporate Management
| Gail Farfel | Chief Officer | Profile | |
| Daniel MBA | Chief Officer | Profile | |
| Johanne Kaplan | Chief Officer | Profile | |
| Dennis Chen | Head Consultant | Profile | |
| David Wishart | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProMIS Neurosciences. If investors know ProMIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProMIS Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.04 | Revenue Per Share 0.001 | Return On Assets (4.81) | Return On Equity (10.99) |
The market value of ProMIS Neurosciences is measured differently than its book value, which is the value of ProMIS that is recorded on the company's balance sheet. Investors also form their own opinion of ProMIS Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is ProMIS Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProMIS Neurosciences' market value can be influenced by many factors that don't directly affect ProMIS Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProMIS Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProMIS Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.